Head and Neck Cancer Research Report 2023 - Global Trends, Analysis and Forecasts to 2032 - Anti-PD-Monoclonal Antibodies Lead the Charge in Treatment

DUBLIN, Aug. 8, 2023 /PRNewswire/ -- The "Head and Neck Cancer Market, [By Cancer Type , By Diagnostic Techniques, By Treatment Type, By End Use, and Geography - Trend, Analysis and Forecast till 2032" report has been added to  ResearchAndMarkets.com's offering.

The global head and neck cancer market size is expected to reach USD 4,523.43 million by 2032

The head and neck cancer industry is expected to grow at the quickest rate over the forecast period owing to increasing global alcohol and tobacco-consuming consumers and the geriatric population.

Head and neck cancer disorders are generally characterized by cancer in the squamous cells present in the lining of the mouth, voice box (larynx), and throat (pharynx). The disorder can also be found in various parts such as sinuses, salivary glands, and muscles or nerves.

Head and neck cancer is considered the seventh most common cancer globally and contributes to more than 8,00,000 new cases annually, as per the National library of medicine. As per the National Institute of Cancer, the major reasons for head and neck cancer disorder can be attributed to continuous alcohol and tobacco use, infection with cancer-causing human papillomavirus, occupational exposure, radiation exposure, and other underlying genetic condition.

Common symptoms witnessed in the disorder are a lump in the neck, sore mouth, difficulty swallowing, hoarseness in the voice, white or red patches on the gums, bleeding through the nose, swelling under the chin, and numbness or paralysis of the muscles in the face.

The major restraining factors for the head and neck cancer market are expensive diagnosis therapies and the unavailability of well-developed cancer treatment clinics across underdeveloped countries.

Head and neck cancer Market Report Highlights

• The covid-19 pandemic harmed the head and neck cancer market. Factors such as limited inpatient services, fear of contact with healthcare providers, and telemedical visits during the pandemic led to a delayed diagnosis for the head and neck cancer market.
• In the drug class, the anti-PD-monoclonal antibodies segment is anticipated to dominate the market. The major factor behind the growth can be attributed to the higher efficiency of the drug against the cancer cells. Monoclonal antibodies such as PD-1 and PD-L1 effectively target the checkpoint proteins that attack the body's cancer cells.
• In the distribution channel segment, the hospital pharmacy is anticipated to dominate the market in 2022 due to increasing demand for cancer-treating drugs and therapies from rising admission of head and neck cancer patients in private hospitals and public hospitals globally.
• In the forecast period, the North America region is projected to dominate the head and neck cancer market owing to a larger share of patients and their expenditure on treating head and neck cancer. The continuous R&D on new drugs and drugs approved by the US Food and Drug Administration (FDA) has increased the demand for more effective therapies from all over the world and further fueled the market in the region.

Market Dynamics

Drivers and Opportunities

• Increasing prevalence of head and neck cancers
• Rising geriatric population

Restraints and Challenges

• High cost of treatments

Market Trends

• Porter's Five Forces Analysis
• PESTLE Analysis
• Head and Neck Cancer Industry Trends
• Value Chain Analysis
• COVID-19 Impact Analysis

Company Profiles

• Bayer Healthcare AG
• Boston Biomedical Inc.
• Bristol-Myers Squibb Company
• Astellas Pharma Inc.
• AbbVie Inc.
• AstraZeneca Plc.
• Acceleron Pharma Inc.
• DentalEZ Inc.
• Koninklijke Philips N.V.
• Siemens Healthcare Private Limited
• AB Sciences
• AdDent Incorporated

Scope of the Report

Head and neck cancer Market, Drug class Outlook (Revenue - USD Million, 2019 - 2032)

• Phosphodiestrase-4 Inhibitors
• Anti-PD-1 Monoclonal Antibodies
• Long-Acting Bronchodilators
• Short-Acting Bronchodilators
• Methylxanthines
• Corticosteroids

Head and neck cancer Market, COPD Outlook (Revenue - USD Million, 2019 - 2032)

• Chronic Bronchitis
• Emphysema

Head and neck cancer Market, Treatment Type Outlook (Revenue - USD Million, 2019- 2032)

• Drugs
• Oxygen therapy
• Surgery
• Others

Head and neck cancer Market, Distribution Channel Outlook (Revenue - USD Million, 2019- 2032)

• Hospitals Pharmacies
• E-Commerce
• Retail Pharmacies

Head and neck cancer Market, Regional Outlook (Revenue - USD Million, 2019 - 2032)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Latin America
• Argentina
• Brazil
• Mexico
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa

For more information about this report visit https://www.researchandmarkets.com/r/hgde3r[by-cancer-type?w=5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets